1. Home
  2. VLYPO vs EXEL Comparison

VLYPO vs EXEL Comparison

Compare VLYPO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLYPO
  • EXEL
  • Stock Information
  • Founded
  • VLYPO N/A
  • EXEL 1994
  • Country
  • VLYPO United States
  • EXEL United States
  • Employees
  • VLYPO 3732
  • EXEL N/A
  • Industry
  • VLYPO Major Banks
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VLYPO Finance
  • EXEL Health Care
  • Exchange
  • VLYPO Nasdaq
  • EXEL Nasdaq
  • Market Cap
  • VLYPO N/A
  • EXEL 9.8B
  • IPO Year
  • VLYPO N/A
  • EXEL 2000
  • Fundamental
  • Price
  • VLYPO $25.11
  • EXEL $36.17
  • Analyst Decision
  • VLYPO
  • EXEL Buy
  • Analyst Count
  • VLYPO 0
  • EXEL 18
  • Target Price
  • VLYPO N/A
  • EXEL $37.59
  • AVG Volume (30 Days)
  • VLYPO N/A
  • EXEL 2.2M
  • Earning Date
  • VLYPO N/A
  • EXEL 05-13-2025
  • Dividend Yield
  • VLYPO N/A
  • EXEL N/A
  • EPS Growth
  • VLYPO N/A
  • EXEL 170.77
  • EPS
  • VLYPO N/A
  • EXEL 1.76
  • Revenue
  • VLYPO N/A
  • EXEL $2,168,701,000.00
  • Revenue This Year
  • VLYPO N/A
  • EXEL $5.78
  • Revenue Next Year
  • VLYPO N/A
  • EXEL $10.94
  • P/E Ratio
  • VLYPO N/A
  • EXEL $20.64
  • Revenue Growth
  • VLYPO N/A
  • EXEL 18.50
  • 52 Week Low
  • VLYPO N/A
  • EXEL $20.14
  • 52 Week High
  • VLYPO N/A
  • EXEL $40.26
  • Technical
  • Relative Strength Index (RSI)
  • VLYPO 62.15
  • EXEL 43.89
  • Support Level
  • VLYPO $24.55
  • EXEL $34.90
  • Resistance Level
  • VLYPO $25.39
  • EXEL $40.26
  • Average True Range (ATR)
  • VLYPO 0.29
  • EXEL 1.21
  • MACD
  • VLYPO 0.12
  • EXEL -0.19
  • Stochastic Oscillator
  • VLYPO 82.83
  • EXEL 23.69

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: